{
    "clinical_study": {
        "@rank": "122560", 
        "arm_group": [
            {
                "arm_group_label": "Prednisolone", 
                "arm_group_type": "Experimental", 
                "description": "Prednisolone Sodium Phosphate Ophthalmic Solution, 1%"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Tears Naturale II Ophthalmic Solution, 1%"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effectiveness of the modified Conjunctival\n      Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to\n      treatment with a proven ocular anti-inflammatory medication,\n\n      Prednisolone, assessed by the following measures:\n\n      Chronic Allergic Inflammation assessed using confocal microscopy Ocular itching Conjunctival\n      redness"
        }, 
        "brief_title": "Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Allergic Conjunctivitis", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Prospective, single center, randomized, double-masked, placebo controlled study. Subjects\n      will be randomized to one of the following treatment arms to dose four times per day (QID)\n      for 4 days between Visits 3 and 4.\n\n      Prednisolone phosphate Tears Naturale II Ophthalmic Solution (Placebo)\n\n      Duration:\n\n      Approximately 2 weeks\n\n      Controls:\n\n      Artificial Tears (Tears Naturale\u00ae II)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age & either sex, any race\n\n          -  Willing and able to follow all instructions\n\n          -  Positive history of ocular allergies\n\n          -  Reproducible positive ocular allergic reaction induced by conjunctival\n             allergen challenge\n\n        Exclusion Criteria:\n\n          -  Have planned surgery during trial period\n\n          -  Female currently pregnant, planning a pregnancy or lactating\n\n          -  Use of disallowed medications\n\n          -  Have ocular infections, or ocular conditions that could affect study parameters\n\n          -  Have moderate to severe dry eye\n\n          -  Have used an investigational drug or device within 30 days of start of study\n\n          -  Female that is currently pregnant, planning a pregnancy or lactating"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01730872", 
            "org_study_id": "12-270-0007"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prednisolone", 
                "description": "One drop in each eye, four times/day for 4 days.", 
                "intervention_name": "Prednisolone Sodium Phosphate Ophthalmic Solution 1%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "one drop in each eye, four times/ day (QID) for 4 days", 
                "intervention_name": "Tears Naturale II Ophthalmic Solution", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Prednisolone", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate", 
                "Sodium phosphate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Andover", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01810"
                }, 
                "name": "Andover Eye Associates"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model", 
        "overall_official": {
            "affiliation": "Massachusetts Medical Society, Alpha Omega Alpha Honor Society, American Academy of Ophthalmology", 
            "last_name": "Gail Torkildsen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Visit 3A compared to Visit 5A", 
            "measure": "Inflammation", 
            "safety_issue": "No", 
            "time_frame": "90 minutes post CAC"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01730872"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Visit 3B compared to 5B", 
                "measure": "Ocular Itching", 
                "safety_issue": "No", 
                "time_frame": "3 minutes post CAC"
            }, 
            {
                "description": "Visit 3B compared to 5B", 
                "measure": "Ocular Redness", 
                "safety_issue": "No", 
                "time_frame": "7 minutes post-CAC"
            }
        ], 
        "source": "ORA, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ORA, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}